CBSET, a not-for-profit preclinical research institute, announced that its scientists have defined the optimal tissue debulking protocol for treating in-stent restenosis (ISR) with Boston Scientific’s Jetstream Navitus atherectomy device. These findings were disclosed at the Cardiovascular Research Technologies 2015 annual scientific meeting (CRT 2015) in Washington, D.C.

Sunshine Heart Inc. announced it has received unconditional approval from the U.S. Food and Drug Administration (FDA) to conduct an interim analysis of COUNTER HF, the company's U.S. pivotal study.

SuperSonic Imagine announced a partnership with U.S.-based Unetixs Vascular Inc. to bring SuperSonic Imagine’s technology to more customers in the vascular market.

In light of a recent American Heart Association report stating that U.S. mitral valve regurgitation prevalence was 1.7 percent in 2014, a significant opportunity exists for development of an effective transcatheter mitral valve replacement (TMVR) device as an alternative treatment to surgery for inoperable patients. This assessment was given by an analyst with research and consulting firm GlobalData.

Daiichi Sankyo and the Heart Rhythm Society announced results from a global survey, which polled cardiologists from around the world and revealed that a majority (58 percent) agree there is no such thing as a "typical" non-valvular atrial fibrillation (NVAF) patient.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now